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Background: Uterine leiomyomas can be classified into molecularly distinct subtypes according to their genetic triggers: MED12
mutations, HMGA2 upregulation, or inactivation of FH. The aim of this study was to identify metabolites and metabolic pathways
that are dysregulated in different subtypes of leiomyomas.
Methods: We performed global metabolomic profiling of 25 uterine leiomyomas and 17 corresponding myometrium specimens
using liquid chromatography–tandem mass spectroscopy.
Results: A total of 641 metabolites were detected. All leiomyomas displayed reduced homocarnosine and haeme metabolite
levels. We identified a clearly distinct metabolomic profile for leiomyomas of the FH subtype, characterised by metabolic
alterations in the tricarboxylic acid cycle and pentose phosphate pathways, and increased levels of multiple lipids and amino
acids. Several metabolites were uniquely elevated in leiomyomas of the FH subtype, including N6-succinyladenosine and
argininosuccinate, serving as potential biomarkers for FH deficiency. In contrast, leiomyomas of the MED12 subtype displayed
reduced levels of vitamin A, multiple membrane lipids and amino acids, and dysregulation of vitamin C metabolism, a finding
which was also compatible with gene expression data.
Conclusions: The study reveals the metabolomic heterogeneity of leiomyomas and provides the requisite framework for
strategies designed to target metabolic alterations promoting the growth of these prevalent tumours.
Uterine leiomyomas are benign, yet extremely common tumours
affecting up to 70% of women by age 50 years (Baird et al, 2003).
Although the majority are asymptomatic, approximately 25% of
affected women display symptoms including abnormal uterine
bleeding and abdominal pain that require medical attention
(Stovall, 2001). As conservative therapies leave room for improve-
ment, patients frequently end up undergoing hysterectomy.
Consequently, the economic and health impact of leiomyomas is
enormous: the estimated annual health-care-related costs of uterine
leiomyomas range from 6 to 34 billion USD in the United States
(Cardozo et al, 2012).
Leiomyomas are oestrogen- and progesterone-dependent
tumours that consist of slowly proliferating smooth muscle cells
surrounded by abundant extracellular matrix (Malik et al, 2010).
An affected uterus may contain multiple leiomyomas that vary
greatly in size and may exceed 20 cm in diameter (Cramer and
Patel, 1990). Molecular analyses have revealed that leiomyomas
harbour mutually exclusive driver mutations (Markowski et al,
2012; Mehine et al, 2014; Kämpjärvi et al, 2016). The most
frequent of these are mediator complex subunit 12 (MED12)
mutations (Mäkinen et al, 2011) and high mobility group AT-hook
2 (HMGA2) translocations (Schoenmakers et al, 1995), which
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affect approximately 80% and 10% of uterine leiomyomas,
respectively (Mehine et al, 2014). Heterozygous germline muta-
tions in the tricarboxylic acid (TCA) cycle enzyme fumarate
hydratase (FH) cause hereditary leiomyomatosis and renal cell
cancer (HLRCC) syndrome, characterised by predisposition to type
2 papillary renal cell carcinoma, as well as uterine and cutaneous
leiomyomas (Tomlinson et al, 2002). These syndromic tumours
display a somatic second-hit mutation in FH, resulting in the
complete loss of FH activity in neoplastic cells. Biallelic inactivation
of FH accounts for only 1% of sporadic leiomyomas (Lehtonen
et al, 2004). Different downstream mechanisms are likely to lead to
the development of leiomyomas, as these three genetic-driver
changes result in clearly distinct gene expression profiles (Mehine
et al, 2016).
Reprogramming of metabolic pathways is a hallmark feature of
neoplastic growth and therapeutic targeting of metabolic altera-
tions is a promising strategy to control the process (Tennant et al,
2010; Pavlova and Thompson, 2016). To our knowledge, no prior
studies exploring the whole metabolome of leiomyomas exist. Here
we used untargeted metabolomic analysis to determine the
pathophysiology of leiomyomas and the metabolic processes that
enable tumour growth and development. This study explored the
global metabolomic profile of 25 leiomyomas, harbouring different
genetic-driver alterations including defects in FH, MED12, or
HMGA2, and 17 respective normal myometrium samples.
Furthermore, we integrated metabolomic and gene expression
data to gain a deeper understanding of the molecular networks that
are dysregulated in leiomyomas. We identified several metabolic
alterations common for all leiomyomas and distinctive character-
istics for leiomyomas of the FH and MED12 subtypes.
MATERIALS AND METHODS
Subjects. The study material was derived from sample collections
described in our previous work (Mäkinen et al, 2011; Heinonen
et al, 2014; 2017; Mehine et al, 2016). Briefly, uterine leiomyoma
and corresponding myometrial tissue samples were collected from
patients undergoing hysterectomy in Finland between 2002 and
2015 and stored fresh frozen at  80 1C. Samples from five patients
(series M) were obtained anonymously with the approval of the
director of the health-care unit. The other patients (series B, My,
and N) signed an informed consent, and clinical data were
available from their patient records. The appropriate Ethics Review
Board of Helsinki University Hospital, Finland approved this
study.
Sample selection. The study samples were selected based on our
previous work: seven leiomyomas were FH deficient (three from
HLRCC patients), seven harboured a mutation in MED12, two
displayed HMGA2 overexpression, and nine were mutation
negative for all three, henceforth termed triple wild-type
leiomyomas. These 25 leiomyomas were obtained from 17 patients
from whom normal myometrium samples were also included in
the study.
All samples were screened for MED12 hotspot mutations using
Sanger sequencing (Kämpjärvi et al, 2016). Deletions and
rearrangements affecting FH or HMGA2 loci were detected using
whole-genome sequencing and/or SNP arrays (Supplementary
Table S1) (Mehine et al, 2016). All tumours with 1q deletion and
corresponding normal samples were screened for FH mutations
using Sanger sequencing (Supplementary Table S1) (Kämpjärvi
et al, 2016). The relative quantification of HMGA2 expression was
determined in all samples with rearrangements or deletions
affecting HMGA2 using gene expression data (Mehine et al,
2016) or HMGA2 qPCR, performed on a 7500 Fast Real-Time PCR
System with Assay No. Hs04397751_m1 (Applied Biosystems,
Darmstadt, Germany), using 18S rRNA as endogenous control
(Supplementary Table S1).
Gene expression profiling. A total of 94 leiomyomas, including
10 with biallelic loss of FH, 34 with a MED12 mutation, 27 with an
HMGA2 rearrangement and 23 triple wild-type leiomyomas, and
60 corresponding myometrium samples were assayed with
Affymetrix GeneChip Human Exon 1.0 ST arrays. The gene
expression profiling is described in detail in Mehine et al (2016).
Metabolomic profiling. Metabolomic profiling was performed by
Metabolon Inc. (Durham, NC, USA) as described previously
(Mesnage et al, 2016). Briefly, samples were analysed using four
independent platforms: two reverse phase/ultra-performance liquid
chromatography–tandem mass spectroscopy (RP/UPLC-MS/MS)
methods with positive ion mode electrospray ionisation (ESI)
chromatographically optimised separately for hydrophilic and
hydrophobic compounds, one for analysis by RP/UPLC-MS/MS
with negative ion mode ESI, and one for analysis by hydrophilic
interaction chromatography/UPLC-MS/MS with negative ion
mode ESI. All methods used an ACQUITY UPLC (Waters,
Milford, MA, USA) and a Q-Exactive high-resolution/accurate
mass spectrometer (Thermo Scientific Inc., Waltham, MA, USA)
interfaced with a heated electrospray ionisation (HESI-II) source
and Orbitrap mass analyser operated at 35 000 mass resolution. A
pooled matrix sample of each experimental sample served as a
technical replicate; extracted water samples served as process
blanks; and a cocktail of quality-control standards spiked into
every analysed sample allowed instrument performance monitor-
ing and aided chromatographic alignment. Compounds were
identified by comparison to library entries of purified standards or
recurrent unknown entities. Peaks were quantified using area
under the curve.
To replicate the clustering results, a targeted analysis of 102
metabolites on 10 normal myometrium samples of uterine
leiomyoma patients was carried out at the Metabolomics Unit,
Technology Centre, Institute for Molecular Medicine Finland
FIMM, University of Helsinki as previously described (Nikkanen
et al, 2016).
Statistical analysis. Statistical analyses were performed with
Partek Genomics Suite version 6.6 (Partek Inc., St Louis, MO,
USA). Raw data of each metabolite were rescaled to set the median
to 1 and log2 transformed. Missing values were imputed with the
minimum observed value for each compound. Principal compo-
nent analysis (PCA) was performed for all samples. Unsupervised
hierarchical clustering analysis (cosine dissimilarity) was per-
formed using all metabolites. The PCA and the unsupervised
hierarchical clustering analysis revealed five outlier samples (M4
m2, M4 m3, M4 N, M11 m2, and M11 N), all of which were
derived from two individual patients (M4 and M11). Both normal
samples were also outliers in the replication data set
(Supplementary Figure S1). These outlier samples were interpreted
as biological outliers and therefore included in the subsequent
analyses.
To evaluate whether tumour size (largest diameter) correlated
with any of the metabolite levels, we calculated Pearson’s
correlation coefficients. A two-way ANOVA, with tissue type
and patient-of-origin as factors, was constructed to identify
metabolites that were dysregulated between leiomyomas and the
corresponding myometrium samples. A one-way ANOVA, with
tissue type as a factor, was constructed to identify metabolites that
were dysregulated in each leiomyoma subtype (FH, MED12,
HMGA2, and triple wild type) as compared with all myometrium
samples. The 20 most significant metabolites from each compar-
ison, yielding 63 unique metabolites, were used for supervised
hierarchical clustering analysis (cosine dissimilarity) of all tumour
and normal samples. To identify the most uniquely dysregulated
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metabolites for leiomyomas of MED12 and FH subtypes, two
three-way ANOVA tests, with mutation status (mutation positive
or negative), tissue type, and patient-of-origin as factors, were
constructed that compared each subtype against the rest of the
leiomyoma and myometrium samples. To identify dysregulated
main categories of metabolites between each leiomyoma subtype
(FH, MED12, HMGA2, and triple wild type) and all myometrium
samples, we used the Partek GO-ANOVA function (metabolite set
ANOVA) with metabolites grouped into nine main categories. To
explore whether any of the 86 metabolic pathways were
significantly dysregulated, a pathway enrichment analysis was
performed with the significant metabolites (q-value o0.1) for each
leiomyoma subtype. False discovery rate control was used to
correct for multiple testing (Benjamini and Hochberg, 1995).
Ingenuity pathway analysis. Ingenuity pathway analysis (IPA)
was carried out with each set of significantly dysregulated
metabolites (q-value o0.1) and each set of significantly differen-
tially expressed genes (q-value o0.1, |fold change (FC)|41.5)
using IPA software version 33559992 (Qiagen, Redwood City, CA,
USA). We used IPA’s comparison tool to identify pathways that
were significantly dysregulated in both the metabolomic and gene
expression data (P-value o0.05 in both) for leiomyomas of the FH,
MED12, and HMGA2 subtypes. We excluded the triple wild-type
leiomyomas from the analyses due to their heterogeneity in the
clustering analyses. Ingenuity Knowledge Base (Genesþ
Endogenous Chemicals) was used as a reference set.
RESULTS
LC-MS/MS identified 588 named and 53 unnamed metabolites
among the 25 leiomyoma and 17 myometrium samples (Figure 1).
Genetic-driver changes had stronger effect on global metabolomic
profiles than menopause status or hormone treatment of the
patients (Supplementary Figure S2A). Leiomyomas of the FH
subtype displayed a clearly distinct metabolomic profile according
to the PCA (Figure 1) and the hierarchical clustering analysis
(Supplementary Figure S2A). Leiomyomas of the FH, MED12, and
HMGA2 subtypes were distinguishable from each other and from
the myometrium based on abundancies of metabolites belonging to
multiple different categories (Figure 2). The metabolites that most
significantly correlated with tumour size were tryptophan betaine
(r¼ 0.65, 95% confidence interval 0.35 to 0.83, q-value¼ 0.082)
and glucose (r¼  0.64, 95% confidence interval  0.83 to  0.33,
q-value¼ 0.089, Supplementary Table S2).
To identify dysregulated metabolites in the complete set of
leiomyomas, we compared all 25 leiomyomas against the corre-
sponding 17 myometrial tissue specimens. Although patient-of-
origin was a major source of variation across all metabolites
(Supplementary Figure S2B), 70 metabolites were significantly
dysregulated between leiomyoma and myometrium samples across
all patients (q-value o0.1, Supplementary Table S3). The most
significant metabolite was homocarnosine (FC  14.7), down-
regulated in all leiomyomas regardless of subtype (Figure 3). To
identify dysregulated metabolites in leiomyomas of the FH, MED12,
HMGA2, and triple wild-type subtypes, we compared leiomyomas of
each subtype against all myometrial tissue specimens. This revealed
170, 104, 35, and 22 significant metabolites, respectively (q-value
o0.1, Supplementary Table S3). Most of the significantly dysregu-
lated metabolites were increased in leiomyomas of the FH (118/170;
69%) and HMGA2 (21/35; 60%) subtypes, whereas in the MED12
(15/104; 14%) and triple wild-type subtypes (4/22, 18%) only a small
proportion of the significantly aberrant metabolite levels showed
increase (Figures 1C and D and 2). Owing to the limited number of
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Figure 1. Overview of the metabolomic data. (A) A total of 641 metabolites were identified in the study. (B) Principal component analysis revealed
five outlier samples (circle) and grouping of leiomyomas of the FH subtype together, while the rest of the samples were intermixed. Venn diagrams
illustrating the number of significantly (C) increased and (D) decreased metabolites (q-value o0.1) among leiomyomas of the FH, MED12, HMGA2,
and triple wild-type subtypes.
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supported by both metabolic and expression data in this subtype or
detectable in multiple subtypes.
Many cofactors and vitamins were altered in all leiomyomas or
in specific subtypes. Haeme and biliverdin, which link to
haemoglobin and porphyrin metabolism, were reduced in all
leiomyoma subtypes (Supplementary Figure S3, Supplementary
Table S3). Ascorbate (vitamin C) and aldarate metabolism was
altered in leiomyomas of the MED12 and triple wild-type subtypes
(Table 1); the level of ascorbate itself remained unaltered, but the
levels of dehydroascorbate, threonate, and gulonate were reduced.
IPA predicted dysregulation of the antioxidant action of vitamin C
pathway in leiomyomas of the MED12 subtype based on both
metabolic and gene expression data (Table 2). Similarly, retinol
(vitamin A) was significantly reduced in the MED12 and triple
wild-type subtypes (FC  2.5 and  1.8, respectively). Based on
previous studies, vitamin D deficiency contributes to the develop-
ment of leiomyomas (Brakta et al, 2015); no vitamin D metabolites
were detected in our study samples.
The alterations affecting amino-acid metabolites varied between
leiomyoma subtypes. FH-deficient leiomyomas displayed signifi-
cant accumulation of urea cycle metabolites argininosuccinate (FC
38.5, Figure 3), proline (FC 1.5, Supplementary Figure S3),
citrulline (FC 1.4), dimethylarginine (FC 2.5), trans-4-hydroxypro-
line (FC 1.7), and N-monomethylarginine (FC 1.6). The levels of
leucine, isoleucine, and valine metabolites 3-methyl-2-oxobutyrate
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Figure 2. Supervised hierarchical clustering analysis with 63 metabolites comprising the 20 most significant metabolites of each leiomyoma
subtype.
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oxovalerate (FC 4.7) were notably elevated in leiomyomas of the
FH subtype. Leiomyomas of the HMGA2 subtype displayed
accretion of the polyamine metabolites N-acetylputrescine (FC
11.3) and N(4)-acetylspermidine (FC 7.7), the latter of which was
also elevated in the FH subtype (FC 5.2). Furthermore, IPA
predicted dysregulation of putrescine degradation III in the
HMGA2 subtype based on both metabolomic and gene expression
data (Table 2). In leiomyomas of the MED12 subtype, the pathway
enrichment analysis of the metabolomic data revealed significant
dysregulation of methionine, cysteine, S-adenosylmethionine
(SAM), and taurine metabolism as well as significant reduction
of dipeptides (Table 1). In addition, multiple amino acids and their
derivatives were specifically decreased in the MED12 subtype,
including histamine (FC  35.9, Figure 3), phenylalanine (FC
 2.2, Figure 3), leucine (FC  1.5, Supplementary Figure S3),
isoleucine (FC  1.5), lysine (FC  1.5), arginine (FC  1.4),
argininosuccinate (FC  1.9, Figure 3), tyrosine (FC  2.0), and
tryptophan (FC  1.5).
Leiomyomas displayed alterations in a wide array of lipid
classes. The pathway enrichment analysis revealed significant
dysregulation of sphingolipid metabolism in all subtypes except
triple wild-type leiomyomas (Table 1). Especially leiomyomas of
the MED12 subtype showed considerable enrichment of sphingo-
lipid alterations characterised by significant reduction of 23 out of
38 (60.5%) detected sphingolipids. In addition, IPA predicted
dysregulation of sphingosine 1-phosphate signalling in the
HMGA2 subtype at both the metabolic and transcriptional levels
(Table 2). Phosphatidylserines were reduced especially in leiomyo-
mas of the MED12 subtype (Table 1). Plasmalogens, diacylglycer-
ols, and monohydroxy fatty acids were primarily elevated in both
the FH and HMGA2 subtypes (Table 1, Supplementary Table S3).
As expected, several components of the TCA cycle were
significantly elevated in leiomyomas of the FH subtype, including
fumarate (FC 12.0, Figure 3), malate (FC 10.5, Supplementary
Figure S3), alpha-ketoglutarate (aKG, FC 5.1), succinate (FC 4.1),
and 2-methylcitrate/homocitrate (FC 2.0). The pathway enrich-
ment analysis confirmed significant dysregulation of TCA cycle
metabolism (Table 1). Both metabolomic and gene expression data
suggested an increased flux through the pentose phosphate
pathway (PPP): activation was supported by upregulation of PPP
enzymes, such as glucose-6-phosphate dehydrogenase (FC 3.7),
phosphogluconate dehydrogenase (FC 3.0), and transketolase (FC
4.3), and depletion of key metabolites (Tables 1 and 2).
To identify the most uniquely dysregulated metabolites as
potential biomarkers for leiomyomas of the FH and MED12
subtypes, we compared leiomyomas of these subtypes against all
the other tumour and normal samples (Supplementary Table S4).
We detected 240 and 75 subtype-specific metabolites (q-value
o0.1) in leiomyomas of the FH and MED12 subtypes, respectively.
Figure 3 illustrates the levels of the most uniquely dysregulated
metabolites for both subtypes. To identify dysregulated main
categories of metabolites, we performed metabolite set ANOVA.
The FH subtype displayed a significant overall increase of energy,
lipid, and nucleotide metabolites, whereas the MED12 subtype
displayed a significant overall decrease of cofactors and vitamins,
peptides, and unnamed metabolites, and the triple wild-type
leiomyomas displayed significant reduction of cofactors and
vitamins (Supplementary Figure S4).
DISCUSSION
This study explored the global metabolomic profiles of 25 uterine
leiomyomas representing the three main molecular subtypes:
leiomyomas driven by FH deficiency, a MED12 mutation, or
HMGA2 upregulation. Altogether 70 metabolites were commonly
dysregulated in all leiomyomas. We found that FH-deficient
leiomyomas represent, as expected, a metabolically distinct subtype
of leiomyomas and that these leiomyomas can be distinguished
based on their metabolomic profile, whereas the metabolic changes
in the other subtypes were subtler. Leiomyomas of the FH subtype
displayed predominantly accumulation of metabolites, whereas the
changes in the MED12 subtype were mainly decreases. It is





























































Figure 3. Levels of the most significantly dysregulated metabolites. Homocarnosine was the most significantly dysregulated metabolite in all
leiomyomas. Fumarate, N6-succinyladenosine (S-ado), and argininosuccinate were the most uniquely dysregulated metabolites in leiomyomas of
the FH subtype. Histamine and phenylalanine were the most uniquely dysregulated metabolites in leiomyomas of the MED12 subtype.
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may limit the supply of building blocks and thereby explain the
significantly smaller size of leiomyomas of the MED12 subtype
(Heinonen et al, 2017).
Leiomyomas of all subtypes displayed reduction of specific
vitamin and other cofactor metabolites, suggesting alterations in
redox state, enzyme function, and signalling pathways. We
detected a significant reduction of retinoic acid (RA) precursor
retinol (vitamin A) in leiomyomas of the MED12 and triple wild-
type subtypes. Furthermore, gene expression data revealed RA
receptor activation as one of the most significantly dysregulated
pathways in leiomyomas (Mehine et al, 2016). Reduced retinol
levels may reflect a decreased concentration of biologically active
RA and increased rate of RA metabolism, which has been
previously observed in leiomyomas (Catherino and Malik, 2007).
Furthermore, all-trans-RA, synthetic retinoid N-(4-hydroxyphe-
nyl)retinamide (4-HPR), and RA metabolism-blocking agent
liarozole have been shown to reduce leiomyoma cell proliferation
and extracellular matrix production (Broaddus et al, 2004;
Malik et al, 2008; Gilden et al, 2012). Essentially, 4-HPR and
liarozole have been well tolerated in clinical studies (Debruyne
et al, 1998; Camerini et al, 2001). The metabolites of ascorbate
(vitamin C) were also depleted, and based on the gene expression
data, the antioxidant action of vitamin C was predicted to be
activated in leiomyomas of the MED12 subtype. In addition to
antioxidant response, these alterations in vitamin C metabolites
may reflect adaptations in other important cellular processes
including DNA and histone demethylation, and the nuclear factor-
kB-mediated signalling (Cárcamo et al, 2004; Young et al, 2015). In
particular, the depletion of vitamin C metabolites may link to the
abundance of extracellular matrix in leiomyomas, as vitamin C is a
cofactor in collagen synthesis (Du et al, 2012). Epidemiological
studies have found no association between vitamin C and
leiomyoma risk, whereas results regarding retinol levels and
leiomyoma risk are contradictory (Martin et al, 2011; Wise et al,
2011), thus further research on their use as preventive agents is
warranted.
As a novel finding, the levels of haeme, a fundamental co-factor
in cellular respiration and signal transduction, and its degradation
product biliverdin were reduced in all leiomyomas, suggesting that
haeme metabolism has an important role in leiomyomagenesis. As
the cataplerotic haeme biosynthesis uses TCA-cycle-derived carbon
and haeme degradation produces bilirubin to be excreted,
increased haeme metabolism promotes removal of accumulated
TCA cycle metabolites especially in FH-deficient leiomyomas, in
which the expression of haeme-degrading-enzyme gene, haeme
oxygenase 1 (HMOX1) is upregulated (Frezza et al, 2011; Mehine
et al, 2016). Moreover, the inhibition of haeme biosynthesis and
degradation pathway has demonstrated to be synthetic lethal with
FH deficiency (Frezza et al, 2011). Although the mechanisms
underlying these alterations in haeme metabolism are likely to be
different in leiomyomas of the FH subtype than in the other
leiomyomas, targeting haeme metabolism may serve as valuable
strategy to treat all leiomyomas, regardless of subtype.
The leiomyoma subtypes harboured multiple different altera-
tions affecting peptide and amino-acid metabolites, which are
necessary building blocks and energy sources for tumours.
Homocarnosine, which is a dipeptide derivative predominantly
found in the central nervous system, was abundant across all
myometrium samples and detected at markedly reduced levels in
all leiomyomas. The biological function of homocarnosine remains
largely unclear, although as an antioxidant it may be important in
counteracting oxidative stress (Kohen et al, 1988). No previous
data seem to exist on the levels of homocarnosine in normal
myometrium and further studies are required to understand the
role of homocarnosine in this tissue type. Specifically, leiomyomas
of the MED12 subtype displayed reduction of various amino acids,
Table 1. Significantly dysregulated pathways predicted from metabolomic data by pathway enrichment analysis for each
leiomyoma subtype







Plasmalogen 5.4 0.0047 7/10 (70.0%) 6/1
Glycogen metabolism 5.3 0.0048 4/4 (100.0%) 4/0
TCA cycle 5.1 0.0059 5/6 (83.3%) 5/0
Sphingolipid metabolism 4.6 0.0096 17/38 (44.7%) 7/10
Pentose phosphate pathway 4.0 0.018 3/3 (100.0%) 0/3
Diacylglycerol 3.3 0.036 8/16 (50.0%) 8/0
MED12
Sphingolipid metabolism 22.6 1.5x1010 23/38 (60.5%) 0/23
Phosphatidylserine 5.5 0.0042 3/3 (100.0%) 0/3
Ascorbate (vitamin C) and aldarate
metabolism
4.2 0.015 3/4 (75.0%) 0/3
Dipeptide 3.2 0.043 4/9 (44.4%) 0/4
Methionine, cysteine, SAM, and
taurine metabolism
3.1 0.044 5/13 (38.5%) 1/4
HMGA2
Plasmalogen 9.5 7.5x105 5/10 (50.0%) 4/1
Sphingolipid metabolism 7.6 0.00053 8/38 (21.1%) 1/7
Diacylglycerol 4.8 0.0085 4/16 (25.0%) 4/0
Fatty acid, monohydroxy 3.6 0.026 2/5 (40.0%) 2/0
Triple wild type
Haemoglobin and porphyrin metabolism 5.0 0.0065 2/4 (50.0%) 0/2
Ascorbate (vitamin C) and aldarate
metabolism
5.0 0.0065 2/4 (50.0%) 0/2
Dipeptide derivative 3.4 0.034 1/1 (100.0%) 0/1
Vitamin A metabolism 3.4 0.034 1/1 (100.0%) 0/1
Abbreviations: SAM¼ S-adenosylmethionine; TCA¼ tricarboxylic acid.
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their derivatives, and dipeptides, possibly reflecting increased
protein synthesis. These leiomyomas showed also enrichment of
dysregulated methionine, cysteine, SAM, and taurine metabolites.
The observed reduction of taurine is compatible with a previous
report (Mazzei et al, 2010). As SAM is the major coenzyme in
reactions with methyl group transfer, these changes may reflect
altered methylation of proteins and DNA in leiomyomas of the
MED12 subtype (Teperino et al, 2010; Pavlova and Thompson,
2016). On the contrary, FH-deficient leiomyomas displayed
accretion of valine, leucine, and isoleucine metabolites, suggesting
that blockage of the TCA cycle impairs the function of the
branched-chain alpha-keto acid dehydrogenase complex, which
belongs to the mitochondrial dehydrogenase complex family and is
essential in the metabolism of these amino acids (Harper et al,
1984). In addition, leiomyomas of the FH and HMGA2 subtypes
displayed accretion of polyamines, which has been implicated in
induction of cell proliferation and reduction of apoptosis (Gerner
and Meyskens, 2004). Targeting polyamine metabolism may prove
an effective therapy or, more importantly, a prevention mechanism
for these leiomyoma subtypes, as indicated by a prior study
showing that treatment with 2-difluoromethylornithine, a well-
tolerated inhibitor of a central enzyme in polyamine synthesis,
limits the growth of leiomyoma cells (Broaddus et al, 2004; Gerner
and Meyskens, 2004).
All leiomyomas displayed alterations in a wide array of lipid
classes, yet with subtype specific differences. Levels of sphingoli-
pids and phosphatidylserines, which are structural components of
cell membranes, were especially reduced in leiomyomas of the
MED12 subtype. Sphingolipids are signal transducers that regulate
apoptosis and proliferation (Ogretmen and Hannun, 2004).
Phosphatidylserines also have a role in signalling pathways and
they mediate humoral and cellular processes, including blood
coagulation and phagocytosis (Vance and Steenbergen, 2005). In
contrast, other important components of cell membranes,
plasmalogens and diacylglycerols, were increased in leiomyomas
of the FH and HMGA2 subtypes. These lipids affect the membrane
properties and facilitate various signalling processes (Gómez-
Fernández and Corbalán-Garcı́a, 2007; Braverman and Moser,
2012). All these deregulations in lipid metabolites presumably
contribute to leiomyoma development on many levels, not only by
providing an energy source and building blocks for membrane
biogenesis during cell growth but also by regulating signalling
pathways involved in proliferation and differentiation.
The most apparent effect of FH deficiency was intracellular
fumarate accumulation, which is considered tumour promoting
(Adam et al, 2011). Additionally, FH-deficient leiomyomas
displayed accumulation of other TCA cycle intermediates malate,
succinate, aKG, and homocitrate. Prior studies using HLRCC-
related tumours, FH-deficient kidney cells and tissues from mice,
and a metastatic kidney cancer cell line from an HLRCC patient
have detected accumulation of fumarate and succinate but have
provided contradicting data on the levels of malate, aKG, and
citrate (Pollard et al, 2005; Frezza et al, 2011; Tong et al, 2011;
Adam et al, 2013; Yang et al, 2013; Zheng et al, 2013).
Furthermore, patients with congenital fumarase deficiency, a rare
autosomal-recessive disorder, display increased levels of fumarate,
succinate, aKG, citrate, and malate in their physiological fluids
(Allegri et al, 2010; Tregoning et al, 2013). Mullen et al (2012)
demonstrated that human-derived FH-deficient kidney cancer cells
use glutamine-dependent reductive carboxylation of aKG to
produce citrate, acetyl coenzyme A, and remaining four-carbon
TCA intermediates. This reductive carboxylation supports fatty
acid synthesis allowing FH-deficient cells to maintain growth
(Mullen et al, 2012). Studies using FH-deficient mouse cell lines,
however, observed no evidence of reductive carboxylation (Frezza
et al, 2011; Adam et al, 2013). As increased aKG/citrate ratio
Table 2. Significantly dysregulated pathways at both the metabolome and transcriptome levels for leiomyomas of the FH,
MED12, and HMGA2 subtypes (P-value o0.05 in both metabolomic and gene expression data)
Gene expression data Metabolomic data
Ingenuity canonical
pathways P-value Z-score Genes P-value Metabolites
FH





0.047 NaN PGD m, G6PD m 0.00041 Gluconic acid-6-phosphate k,
D-ribulose 5-phosphate k
tRNA splicing 0.0011 NaN PDE10A k, PDE3A k, PDE1B m, PDE5A k, PDE8B m,
PDE1A m, PDE1C m
0.0087 Niacinamide m, NADþ k
Gluconeogenesis I 0.025 NaN PGK1 m, ENO1 m, ENO2 m, ME1 m, BPGM m 0.0091 L-malic acid m, NADþ k
IL-10 signalling 0.042 NaN IL33 m, HMOX1 m, SOCS3 k, FOS k, JUN k,
MAP4K4 m
0.020 Haeme k, biliverdine k
Salvage pathways of
pyrimidine ribonucleotides
0.045 NaN DAPK1 k, AK1 m, SGK1 k, PRKAA2 k, CDK6 m, AK4
m, MAP3K8 k, LIMK1 m




0.0022 2.83 PLA2G4A k, PLCB4 k, PLCE1 k, NFKBIA k, PLCG2
k, PLA2R1 k, MAPK10 k, RARRES3 k, SLC2A3 k,
TXNRD1 k
0.019 L-dehydroascorbic acid k,
glutathione disulphide k
Type II diabetes mellitus
signalling
0.0025  1.00 PPARG k, SOCS3 k, NFKBIA k, IRS1 m, CD36 k,
ACSL5 k, PRKAA2 k, MAPK10 k, IRS4 m, ACSL4 k,
MAP3K5 k, PRKD1 m
0.034 Sphingomyelin k, ceramide m
HMGA2
Putrescine degradation III 0.028 NaN ALDH1B1 k, MAOB k, ALDH1A1 k, MAOA k 0.011 N-acetylputrescine m
Sphingosine-1-phosphate
signalling
0.0035  1.51 S1PR3 m, PLCB4 k, PLCE1 k, RND3 k, PLCG2 k,
PDGFRA k, GNAI1 k, PIK3C2G m, AKT3 k, PDGFD
k, PDGFC m
0.039 Sphingomyelin k
Abbreviations: IL¼ interleukin; NaN¼ a z-score cannot be calculated for all Ingenuity canonical pathways. Note: a positive z-score indicates predicted activation, and a negative z-score
indicates predicted inactivation of the enriched pathway.
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triggers reductive glutamine metabolism (Fendt et al, 2013), our
results suggest that reductive carboxylation occurs in FH-deficient
leiomyomas, but isotope-labelling studies using leiomyoma cell
lines would be required for confirmation.
Based on the current knowledge of the tumourigenic mechan-
ism of FH-deficiency, accumulation of intracellular fumarate
activates transcription factor nuclear factor (erythroid-derived 2)-
like 2 (NRF2) (Adam et al, 2011). NRF2 is a master regulator of
antioxidant responses and it redirects glucose and glutamine into
anabolic pathways including the PPP, which is an efficient source
of NADPH (Mitsuishi et al, 2012; Gorrini et al, 2013). The gene
expression data revealed a highly significant activation of NRF2-
mediated oxidative stress response in leiomyomas of the FH
subtype causing, for example, upregulation of HMOX1 (Gorrini
et al, 2013; Mehine et al, 2016). This is further supported by our
metabolomic and gene expression data as FH-deficient leiomyomas
displayed several metabolic alterations known to be affected by
activated NRF2 including increased PPP flux, validating an
observation made previously in FH-deficient kidney cancer cell
lines (Yang et al, 2013). All in all, NRF2 activation supports FH-
deficient cell proliferation by enhancing PPP and generating
NADPH, which is critical for reductive carboxylation of glutamine-
derived aKG, synthesis of fatty acids, and protection against
oxidative stress.
Our analysis discovered putative biomarkers for FH deficiency
including argininosuccinate and N6-succinyladenosine (S-ado).
Argininosuccinate is a precursor to fumarate via argininosuccinate
lyase (ASL) and S-ado is formed by dephosporylation of
adenylosuccinate, a substrate of adenylosuccinate lyase (ADSL)
that normally catalyzes formation of fumarate. FH-deficient cells
seem to control the levels of fumarate by reversing or inhibiting the
reactions catalyzed by ASL and ADSL leading to argininosuccinate
and S-ado accumulation (Adam et al, 2013; Zheng et al, 2013;
Jurecka et al, 2015). FH-deficient kidney specimens from mice as
well as physiological fluids of patients with congenital fumarase
deficiency display increased levels of adenylosuccinate, providing
further support for the inhibition of ADSL activity in FH-deficient
tissues (Allegri et al, 2010; Adam et al, 2013; Tregoning et al, 2013).
The usefulness of S-ado as a biomarker and its tumourigenic role
require further research. Argininosuccinate is normally produced
in the urea cycle. FH-deficient kidney cancers employ exogenous
arginine to produce argininosuccinate and blocking this mechan-
ism reduces proliferation of these cells, suggesting that the arginine
pathway is essential for the growth of FH-deficient tumours (Adam
et al, 2013; Zheng et al, 2013). Intriguingly, clinical studies have
revealed a tolerable profile for an arginine-depleting drug (Ott et al,
2013). Furthermore, Zheng et al (2013) observed abundant
secretion of argininosuccinate into the urine of Fh1-deficient mice
and into the growth media of FH-deficient cell lines. Thus,
argininosuccinate and arginine metabolism may prove to be a
robust metabolic biomarker and a treatment target for HLRCC-
associated tumours, respectively.
Taken together, this study discovered novel metabolic altera-
tions in leiomyomas involving vitamin C, various membrane lipid,
peptide, and amino-acid metabolites (Figure 4), which may be
essential for the growth of specific leiomyoma subtypes. Our
findings show the importance of haeme and polyamine metabolism
and validate the dysregulation of vitamin A in primary leiomyoma
tissues. The results revealed the consequences of impaired TCA
cycle associated with FH-deficient leiomyomas pinpointing
biomarkers and potential therapeutic targets. Importantly, well-
tolerated drugs tested in patient trials exist for many of these
aberrant states.
To our knowledge, this is the first study that employs a global
metabolomics approach to analyse uterine leiomyomas and
corresponding myometrium. We have previously shown that the
main genetic drivers of uterine leiomyomas result in distinct gene
expression profiles (Mehine et al, 2016). Here we show that these
genetic drivers lead to differences in the metabolomic profiles as
well. Our results highlight the diversity of metabolic alterations
that can underlie a similar clinical phenotype. The dysregulated
metabolites identified in this study may prove to be useful
biomarkers and targets for prevention and treatment of uterine
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Figure 4. Schematic of the highlighted metabolic alterations in
leiomyomas of the FH and MED12 subtypes. All leiomyomas displayed
reduced homocarnosine and haeme metabolite levels and subtype-
specific alterations in lipids. (A) FH-deficient leiomyomas displayed
dysregulation of TCA cycle, PPP, and the metabolism of amino acids
and nucleotides. (B) MED12-mutated leiomyomas harboured
alterations affecting retinol, ascorbate, amino acids, and dipeptides.
ADSL¼ adenylosuccinate lyase; ASL¼ argininosuccinate lyase;
BCAA¼branched chain amino acid; BCKDC¼branched-chain alpha-
keto acid dehydrogenase complex; FH¼ fumarate hydratase;
HMOX1¼ haeme oxygenase 1; MED12¼mediator complex subunit
12; NRF2¼nuclear factor (erythroid-derived 2)-like 2; PPP¼pentose
phosphate pathway; S-ado¼N6-succinyladenosine; SAM¼ S-
adenosylmethionine; TCA¼ tricaboxylic acid.
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warranted, especially for leiomyomas with HMGA2 overexpres-
sion. Furthermore, metabolic flux studies are required to determine
whether the observed changes are derived from altered flux
through a pathway or altered synthesis, degradation, or transport
of the metabolites. The metabolomic profile of uterine leiomyomas
will contribute to understanding pathophysiology of uterine
leiomyomas and provides a promising foundation for therapeutic
development.
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Cárcamo JM, Pedraza A, Bórquez-Ojeda O, Zhang B, Sanchez R, Golde DW
(2004) Vitamin C is a kinase inhibitor: dehydroascorbic acid inhibits
IkappaBalpha kinase beta. Mol Cell Biol 24: 6645–6652.
Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F,
Denis L, Marberger JM, Brune D, Rassweiler J, Vangeneugden T,
Bruynseels J, Janssens M, De Porre P (1998) Liarozole–a novel treatment
approach for advanced prostate cancer: results of a large randomized trial
versus cyproterone acetate. Liarozole Study Group. Urology 52: 72–81.
Du J, Cullen JJ, Buettner GR (2012) Ascorbic acid: chemistry, biology and the
treatment of cancer. Biochim Biophys Acta 1826: 443–457.
Fendt SM, Bell EL, Keibler MA, Olenchock BA, Mayers JR, Wasylenko TM,
Vokes NI, Guarente L, Vander Heiden MG, Stephanopoulos G (2013)
Reductive glutamine metabolism is a function of the alpha-ketoglutarate to
citrate ratio in cells. Nat Commun 4: 2236.
Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L,
Micaroni M, Chaneton B, Adam J, Hedley A, Kalna G, Tomlinson IP,
Pollard PJ, Watson DG, Deberardinis RJ, Shlomi T, Ruppin E, Gottlieb E
(2011) Haem oxygenase is synthetically lethal with the tumour suppressor
fumarate hydratase. Nature 477: 225–228.
Gerner EW, Meyskens FL Jr (2004) Polyamines and cancer: old molecules,
new understanding. Nat Rev Cancer 4: 781–792.
Gilden M, Malik M, Britten J, Delgado T, Levy G, Catherino WH (2012)
Leiomyoma fibrosis inhibited by liarozole, a retinoic acid metabolic
blocking agent. Fertil Steril 98: 1557–1562.
Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an
anticancer strategy. Nat Rev Drug Discov 12: 931–947.
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Kämpjärvi K, Mäkinen N, Mehine M, Välipakka S, Uimari O, Pitkänen E,
Heinonen H, Heikkinen T, Tolvanen J, Ahtikoski A, Frizzell N,
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